ArticleBlood advances2020
Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Deep learning-based algorithm for automatic detection of incidental pulmonary embolism on contrast-enhanced CT: a multicenter multivendor study.Radiology advances · 2025Article
- Independent Evaluation of a Commercial AI Software for Incidental Findings of Pulmonary Embolism (IPE) on a Large Hospital Retrospective Dataset.Radiology research and practice · 2025Article
- Clinical characteristic, treatment, and mortality among cancer and non-cancer patients presented with incidental pulmonary embolism.Frontiers in medicine · 2025Article
- The promise and limitations of artificial intelligence in CTPA-based pulmonary embolism detection.Frontiers in medicine · 2025Review
- Review
- Practice Variations in the Diagnosis and Treatment of Pulmonary Embolism.Pulmonary medicine · 2024Article
- Incidental venous thrombosis in oncology in a sub-Saharan tertiary hospital.Ecancermedicalscience · 2024Article
- Validation of the HULL Score clinical prediction rule for unsuspected pulmonary embolism in ambulatory cancer patients.ERJ open research · 2023Article
- Prognosis of incidental pulmonary embolism vs. symptomatic pulmonary embolism in cancer patients: a single-center retrospective cohort study in China.Thrombosis journal · 2023Article
- Article
- Artificial Intelligence Tool for Detection and Worklist Prioritization Reduces Time to Diagnosis of Incidental Pulmonary Embolism at CT.Radiology. Cardiothoracic imaging · 2023Article
- Pulmonary Embolism in the Cancer Associated Thrombosis Landscape.Journal of clinical medicine · 2022Review
- Concomitant Deep Vein Thrombosis in Cancer Patients with Unsuspected Pulmonary Embolism.Cancers · 2022Article
- Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter-related thrombosis.Research and practice in thrombosis and haemostasis · 2022Article
- Emergency management of incidental pulmonary embolism (IPE).Emergency cancer care · 2022Review
- Cancer patients' experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study).PloS one · 2022Observational
- Incidentally Diagnosed With Pulmonary Embolism in Lung Cancer Patients: Comparison of Clinical Characteristics and Mortality With Symptomatic Pulmonary Embolism.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incidental pulmonary embolisms (IPEs) are common in cancer patients. Examining the characteristics and outcomes of IPEs in cancer patients can help to ensure proper management, promoting better outcomes. To determine the clinical characteristics, management, and outcomes of IPEs for cancer patients, we conducted a 1:2 ratio case-control study and identified all consecutive patients with IPE who visited the emergency department at The University of Texas MD Anderson Cancer Center between 1 January 2006 and 1 January 2016. Each IPE case was matched with 2 controls using a propensity score obtained using logistic regression for IPE status with other factors affecting overall survival. A total of 904 confirmed cases were included in the analysis. IPE frequently occurred during the first year after cancer diagnosis (odds ratio [OR], 2.79; 95% confidence interval [95% CI], 2.37-3.29; P < .001). Patients receiving cytotoxic chemotherapy had a nearly threefold greater risk of developing IPE (OR, 2.87; 95% CI, 2.42-3.40; P < .001). In-hospital mortality was 1.9%. The 7- and 30-day mortality rates among the cases were 1.8% and 9.9%, respectively, which was significantly higher than in the control groups: 0.2% and 3.1%, respectively (P < .001). IPE was associated with reduced overall survival (hazard ratio [HR], 1.93; 95% CI, 1.74-2.14; P < .001). Concurrent incidental venous thromboembolism was identified in 189 of the patients (20.9%) and was also associated with reduced overall survival (HR, 1.65; 95% CI, 1.21-2.25; P = .001). Our results show that IPE events are associated with poor outcomes in cancer patients. Proper management plans similar to those of symptomatic pulmonary embolisms are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.